10x Genomics Raises Annual Revenue Outlook to $625m–$635m After 1% Quarterly Growth
The research-tools maker reported $150.7m in third-quarter sales and a 75% gross margin, and said its Atera platform is now shipping to customers worldwide.
10x Genomics has raised its full-year 2026 revenue outlook to between $625 million and $635 million, even though third-quarter sales rose only 1%. The company reported the results on 5 November. The range it replaces was not included in the information available, so the size of the increase cannot be stated.
Third-quarter revenue was $150.7 million. Gross margin was 75%, and the company recorded a net loss of $19.4 million. That loss was smaller than in the same quarter a year earlier, though the prior-year figure was not provided. The company ended the period with $575.7 million in cash and marketable securities.
On the product side, 10x Genomics said commercial shipments of Atera have started globally. It also unveiled Sentira, a cloud-hosted software offering for analysing data. No technical specifications, pricing or customer information were available for either product, so their contribution to the revised outlook is unclear.
The company did not say in the material available how much of the higher guidance depends on Atera shipments, and this report does not infer a link.
Why it matters
- Atera is now shipping globally, which labs and procurement teams can factor into evaluations of spatial and single-cell tools. Pricing and specifications have not been disclosed.
- Sentira is a cloud-based product, so groups working in regulated or quality-controlled settings may want to ask about data handling and software validation. No details on these points were supplied.
- A guidance range of $625m–$635m, 75% gross margin and $575.7m in cash and marketable securities are the main financial markers for anyone assessing 10x Genomics as a supplier.
Company's press release (SEC filing): 10x Genomics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
